Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 801–900 of 2,039
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 13
“Other studies have also shown that semaglutide was not associated with an increased risk of any types of cancer [28]. type 2 Diabetes over a period of 40 weeks [30 ].”
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes
Derington, C. G., Sarwal, A., Wei, G., Hartsell, S. E., Throolin, M. J., Singh, R., Nevers, M. R., Zhang, C., Katkam, N., Takyi, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37297 · Cited by 13
Castagneto‐Gissey, L., Casella-Mariolo, J., & Mingrone, G. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_565 · Cited by 13
Is polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?
Hedner, J. A., & Zou, D. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000920 · Cited by 10
“The effect of tirzepatide was noninferior and superior to semaglutide on glycaemic control and weight reduction at 40 weeks in patients with type-2 diabetes [67].”
BackgroundWong, E., Cope, R. J., Dima, L., & Nguyen, T. K. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001588 · Cited by 17
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“SURPASS-2 showed that tirzepatide at all doses (5 mg, 10 mg and 15 mg weekly) was superior to 1 mg of semaglutide (the maximal dose marketed for diabetes treatment) for both glycemic improvement and weight loss [51], noting however that the maximal dose for the obesity indication for semaglutide is 2.”
BackgroundAlba, A. C., Kirklin, J. K., Cantor, R. S., Deng, L., Ross, H. J., Jacobs, J. P., Rao, V. A., Hanff, T. C., & Stehlik, J. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.06.003 · Cited by 10
How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
Gou, Y., & Schwartz, M. W. (2023) · Journal of Clinical Investigation · doi:10.1172/jci174597 · Cited by 9
“In 2022, tirzepatide, which incorporates agonists of both GIP and GLP-1 receptors into a single molecule, was approved by the FDA for T2D.”
BackgroundInfluentialAn Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 16
“The study concluded that tirzepatide is non-inferior and superior to semaglutide in reducing weight and mean glycated hemoglobin level; however, more subjects experienced adverse events [27].”
BackgroundNovel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Novel Drugs for Diabetes Therapy
Heise, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_574 · Cited by 12
Khadanga, S., Barrett, K. V., Sheahan, K. H., & Savage, P. D. (2022) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000761 · Cited by 11
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
Neeland, I. J., McGuire, D. K., & Sattar, N. A. (2021) · Circulation · doi:10.1161/circulationaha.121.056742 · Cited by 9
Klein, M. P., Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241245680 · Cited by 13
“20 As Semaglutide has been shown to have a greater impact on weight loss than Liraglutide, Dulaglutide, and Exenatide, 21-23 Tirzepatide may do so as well.”
Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_16_23 · Cited by 8
Osumili, B., Fan, L., Paik, J. S., Pantalone, K. M., Ranta, K., Sapin, H., & Tofé, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111717 · Cited by 8
Polyagonists in Type 2 Diabetes Management
Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8
“Furthermore, significant blood pressure reduction (SBP/ DBP 2.8–12.6/0.8–4.5 mmHg) were observed in SURPASS trials [40 •• , 41–44].”
InfluentialGlucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
The unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes
Sjöholm, Å. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004291 · Cited by 10
Effectiveness of screening for foot complications in people with diabetes – A systematic review
Staniszewska, A., Jones, A., Rudd, S., de Vocht, F., & Hinchliffe, R. J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108865 · Cited by 12
Cimellaro, A., Cavallo, M., Mungo, M., Suraci, E., Spagnolo, F., Addesi, D., Pintaudi, M., & Pintaudi, C. (2024) · Medicina · doi:10.3390/medicina60091542 · Cited by 12
Ghareb, N., Darwish, K. M., Nafie, M. S., Elrayess, R. A., Abourobe, N. M., Fattah, S. A., Hazem, R. M., Mehanna, E. T., & Elrayess, R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00594e · Cited by 12
Hegab, I. I., El‐Horany, H. E., Abd‐Ellatif, R. N., Nasef, N. A., okasha, A. H., Emam, M. N., Hassan, S., Elseady, W. S., Radwan, D. A., El‐Esawy, R. O., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010001 · Cited by 15
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Rasouli, N., Wilding, J. P. H., Kwan, A. Y. M., Paik, J. S., Sharma, P., & Peleshok, J. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01711-0 · Cited by 16
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes
Patti, A. M., Giglio, R. V., Ciaccio, M., Stoian, A. P., Salmen, T., Bica, I.-C., Rangraze, I. R., El‐Tanani, M., Rizzo, M., & Rizvi, A. A. (2025) · Medicina · doi:10.3390/medicina61040664 · Cited by 9
Molecular Design of Unimolecular Tetra-Receptor Agonists
Dinsmore, T. C., Cortigiano, J. E., Xiang, S., Spenciner, M. V., Dobbins, A. R., Zhao, R. R., Waldman, B. M., Beinborn, M., & Kumar, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04095 · Cited by 13
Munawar, N., Mahato, A., Rawat, A., Gill, F. S., Kumar, D., Katwal, S., Wei, C. R., & Ali, N. (2025) · Cureus · doi:10.7759/cureus.86080 · Cited by 20
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
“A clustering approach – using comorbidities, or phenotypes, – offers a pragmatic fi rst step towards tailoring treatment (73, 74).”
Nunns, M., Febrey, S., Buckland, J., Abbott, R. A., Whear, R., Bethel, A. C., Boddy, K., Shaw, L., Coon, J. T., & Meléndez‐Torres, G. J. (2024) · Health Technology Assessment · doi:10.3310/skht8119 · Cited by 10
Pearson, E. R., Prato, S. D., Pavo, I. J., Franco, D. R., Zheng, J., Nicolay, C., Hemmingway, A., Wiese, R. J., & Kahn, S. E. (2025) · Diabetes · doi:10.2337/db25-0276 · Cited by 13
Vilsbøll, T., Malecki, M. T., Sharma, P., Thieu, V. T., Chivukula, K. K., & Kiljanski, J. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16592 · Cited by 12
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Basile, C., Merolla, A., Mancusi, C., Luca, C. D., Fucile, I., Canonico, M. E., Giugliano, G., Orso, F., Morisco, C., & Esposito, G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf560 · Cited by 17
Henney, A. E., Riley, D. R. J., Anson, M., Azmi, S., Alam, U., & Cuthbertson, D. J. (2025) · Liver International · doi:10.1111/liv.70367 · Cited by 11
Henney, A. E., Riley, D. R. J., Heague, M., Roberts, C. A., Hydes, T., Anson, M., Hughes, D. M., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70169 · Cited by 12
Fadini, G. P., Giaccari, A., Broglio, F., Nollino, L., Fattor, B., Anichini, R., Meregalli, G., Avogaro, A., Consoli, A., Aimaretti, G., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101499 · Cited by 18
Enzan, N., Miyazawa, K., Koyama, S., Kurosawa, R., Ieki, H., Yoshida, H., Takechi, F., Fukuyama, M., Osako, R., Tomizuka, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64659-6 · Cited by 13
“10a and Supplementary Data 39).”
Lin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 8
Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108150 · Cited by 10
Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease
Ma, J., Tao, M., Zhang, W., Zhou, L., Zhang, H., Li, F., Zhang, H., Yao, D., Lu, W., & Wang, M. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1715024 · Cited by 13
Lev, D., Leibowitz, A., Lang, A., Shlomai, G., Twig, G., Eden-Friedman, Y., Engel, T., Cukierman-Yaffe, T., Dankner, R. S., Gerstein, H. C., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106571 · Cited by 13
Miramontes‐González, J. P., Rodrigo-Alaíz, Á., Gabella-Martín, M., Calle, D. G., Carretero-Gómez, J., & Corral-Gudino, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01829-1 · Cited by 11
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2025.106119 · Cited by 16
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
Mizoguchi, M., Takemori, H., Furukawa, S., Ito, M., Asai, M., Morino, H., Miura, T., Yabe, D., & Shibata, T. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0260 · Cited by 8
HIV and obesity: updates in management strategies
Parra-Rodriguez, L., & O’Halloran, J. A. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000781 · Cited by 10
Pharmacotherapy for chronic obesity management: a look into the future
Abdel-Malek, M., Yang, L., & Miras, A. D. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03237-4 · Cited by 13
“Another 40-week trial (SURPASS-2) in 1879 T2DM patients on metformin monotherapy further demonstrated that Tirzepatide at all doses was superior to the GLP-1 RA, Semaglutide 1 mg once weekly, in reducing HbA1c as well weight from baseline [47].”
BackgroundMody, R., Meyer, K. L., Ward, J. M., & O’Day, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01470-w · Cited by 10
“Clinical data were obtained from the SURPASS-2 clinical trial [15] and the SURPASS-2 clinical trial post-hoc analysis [22] (See Table S1 in the electronic supplementary material for details).”
BackgroundMethodInfluentialSabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
Bi, Y., Lu, S., Tang, J., Du, L., & Ji, L. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01561-2 · Cited by 10
Current State of Pharmacotherapy in Obesity
Kim, W. J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.016 · Cited by 10
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Management of Cardiovascular Risk in the Non‑alcoholic Fatty Liver Disease Setting
Luque-Linero, P., & Castilla‐Guerra, L. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.19 · Cited by 14
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat, J., Shah, N. P., Agarwala, A., Khan, M. S., & Butler, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01214-6 · Cited by 11
Morissette, A., & Mulvihill, E. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13065 · Cited by 8
Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
Khurana, A., Rabbani, S. A., El‐Tanani, M., Arora, M. K., Sharma, S., Dubey, H., Aljabali, A. A. A., & Tambuwala, M. M. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101805 · Cited by 13
A new era in gut hormone-based pharmacotherapy for people with obesity
Firman, C., & Batterham, R. L. (2022) · Proceedings of The Nutrition Society · doi:10.1017/s0029665122002695 · Cited by 10
“%) with the 5 mg, 10 mg and 15 mg doses, respectively, compared with a 5.7 kg weight reduction with semaglutide (88) .”
BackgroundInfluentialGlucagon‐like peptide 1 receptor agonists in heart failure: the need for a rewind
Ferreira, J. P., & Neves, J. S. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2693 · Cited by 8
Obesity and diabetes in people of African ancestry with HIV
Cechin, L., Norcross, C., Oliveira, A., Hopkins, D., McGowan, B. M., & Post, F. A. (2022) · HIV Medicine · doi:10.1111/hiv.13413 · Cited by 7
“Tirzepatide resulted in a mean percentage weight reduction of 15%–21% over 72 weeks, which was accompanied by improvements in functional status, waist circumference, systolic blood pressure, plasma lipids, and fasting insulin and glucose [69], while earlier trials have shown high efficacy of tirzepatide in the managem…”
ResultGut–hormone triple agonists: clinical safety and metabolic benefits
Müller, T. D., & Tschöp, M. H. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02350-9 · Cited by 8
Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review
Teague, M., Martinez, A., Walker, E., El-Rifai, M., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.003 · Cited by 8
Ishii, H., Oura, T., & Takeuchi, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01485-3 · Cited by 10
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamusPreprint
Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S. H., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557967 · Cited by 8
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
Oteng, A., Liu, L., Cui, Y., Gavrilova, O., Lü, H., Chen, M., Weinstein, L. S., Campbell, J. E., Lewis, J. E., Gribble, F. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182325 · Cited by 8
“The temporal pronounced reductions in body weight and striking improvements in blood glucose control (18, 19).”
Gong, J., Gao, F., Jiang, K., Xie, Q., Zhao, X., & Lei, Z. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14340 · Cited by 20
“Placebo was mainly used in the control group, and insulin 16,21,22 , dulaglutide 24,26 , and semaglutide 23,27 were used in 3, 2, and 2 studies, respectively.”
Tian, X., Wang, W., Zhang, L., Wang, L., Zhang, K., Ge, X., Luo, Z., Zhao, Y., Zhai, X., & Li, C. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s492626 · Cited by 8
Hamamoto, Y., Oura, T., & Hirase, T. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01704-z · Cited by 10
“…occur via both weight loss-associated and weight loss-unassociated mechanisms, with the latter mediated by GIP receptor agonism [16], which may account for the superior efficacy of tirzepatide over selective GLP-1 receptor agonists observed in SURPASS participants with T2D [5, 9, 10, 12, 13, 17].”
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“There is no increased risk of hypoglycemia, and the ability to lower HbA1c is superior to Semaglutide [52,53].”
Alfehaid, L., Yami, M. S. A., Almohareb, S. N., Alshaya, O. A., & Almutairi, A. R. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2465870 · Cited by 13
Treating obesity in patients with depression: a narrative review and treatment recommendation
Kushner, P. R., Kahan, S. I., & McIntyre, R. S. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2478812 · Cited by 10
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Yamauchi, T., Asakura, T., Shingaki, T., Oura, T., & Katagiri, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16500 · Cited by 10
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 13
Obesity Epidemic and Its Impact on Female Fertility: Current Understanding and Future Directions
Malhotra, R., de Paredes, J. G., Smith, A. C., Chemerinski, A., Doshi, D., & Morelli, S. S. (2025) · Cureus · doi:10.7759/cureus.87283 · Cited by 26
Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., & Pilone, V. (2025) · Nutrients · doi:10.3390/nu17152409 · Cited by 14
Chakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
Self-citationEfficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 11
Angelopoulos, N., Livadas, S., Androulakis, I., Petkova, V., Rizoulis, A. A., Boniakos, A., Paparodis, R. D., Tzoulis, P., Mentzelopoulou, V., Florakis, D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109181 · Cited by 11
Mehta, M., Rometo, D. A., Gusenoff, J. A., & Rubin, J. P. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012672 · Cited by 16
Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications
Shah, J., Razavi, P., Festok, M., Ahmed, H., Mahrous, M. A., Kovacs, K. D., & Kiss, S. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.01.013 · Cited by 13
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“When multiple publications originated from the same clinical research program, the most recent or most comprehensive report was used as the primary source.”
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Zoungas, S., D’Alessio, D. A., Pavo, I. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00032-x · Cited by 16
Mey, J. T., Vandagmansar, B., Dantas, W. S., Belmont, K. P., Axelrod, C. L., & Kirwan, J. P. (2023) · Acta Physiologica · doi:10.1111/apha.14054 · Cited by 7
“Well-established countermeasures to insulin resistance include lifestyle factors, such as hypocaloric diets and exercise, 2,3 pharmacologic approaches 4 or metabolic surgery.”
Navigating the Role of Anti-Obesity Agents Prior to Pregnancy: A Narrative Review
Goldberg, A. S., Dolatabadi, S., Dutton, H., & Benham, J. L. (2023) · Seminars in Reproductive Medicine · doi:10.1055/s-0043-1776795 · Cited by 9
Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report
He, Z., TABE, A., Rana, S., & King, K. (2023) · Cureus · doi:10.7759/cureus.50112 · Cited by 15
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Lisco, G., Disoteo, O., Geronimo, V. D., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Jirillo, E., & Triggiani, V. (2024) · Endocrines · doi:10.3390/endocrines5010005 · Cited by 8
Otsuka, E., Kitamura, M., Funakoshi, S., Mukae, H., & Nishino, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362242 · Cited by 8
“Similarly, tirzepatide improved glycemic control compared with semaglutide and insulin degludec (Frías et al., 2021; Ludvik et al., 2021).”
BackgroundInfluentialPetrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic
Chen, W., Xian, S., Webber, B., DeWolf, E. L., Schmidt, C. R., Kilmer, R., Liu, D., Power, E. M., & Webber, M. J. (2024) · ACS Nano · doi:10.1021/acsnano.4c10248 · Cited by 8
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.